 | | Vol. 10.20 – 18 May, 2022 |
| |
|
|
Disrupting Autorepression Circuitry Generates “Open-Loop Lethality” to Yield Escape-Resistant Antiviral Agents | Researchers found that nucleic-acid decoys mimicking cis-regulatory sites acted as “feedback disruptors,” broke homeostasis, and increased viral transcription factors to cytotoxic levels (termed “open-loop lethality”).
[Cell] |
|
|
|
| | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
MAIT Cell Compartment Characteristics Are Associated with the Immune Response Magnitude to the BNT162b2 mRNA Anti-SARS-CoV-2 Vaccine | Mucosa-associated invariant T (MAIT) cell levels, phenotype and function in circulation were preserved and unperturbed through day 35 post-vaccination in healthy donor vaccinees, as well as people living with HIV or with primary immunodeficiency .
[Trends in Molecular Medicine] |
|
|
|
Vaccine-Induced Systemic and Mucosal T Cell Immunity to SARS-CoV-2 Viral Variants | Using adjuvanted spike protein–based vaccines that elicit potent T cell responses, investigators assessed whether systemic or lung-resident CD4 and CD8 T cells protected against SARS-CoV-2 variants in the presence or absence of virus-neutralizing antibodies.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
The Risk of COVID-19 Death Is Much Greater and Age Dependent with Type I IFN Autoantibodies | With a sample of 1,261 unvaccinated deceased patients and 34,159 individuals of the general population sampled before the pandemic, scientists estimated both infection fatality rate and relative risk of death across age groups for individuals carrying autoantibodies neutralizing type I interferons, relative to noncarriers.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
A Single Dose of BNT162b2 mRNA Vaccine Induces Airway Immunity in SARS-CoV-2 Naive and Recovered COVID-19 Subjects | Parenteral booster injection of a vaccine against a mucosal pathogen promotes stronger mucosal immune responses following prior mucosal infection compared to injections of a parenteral vaccine in a mucosally naive subject. Researchers investigated whether this was also the case for the BNT162b2 COVID-19 mRNA vaccine.
[Clinical Infectious Diseases] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
Host and Pathogen Response to Bacteriophage Engineered against Mycobacterium abscessus Lung Infection | Mycobacterium abscessus isolated pre and post-phage treatment demonstrated genetic stability, with a general decline in diversity and no increased resistance to phage or antibiotics.
[Cell] |
|
|
|
Atypical B Cells Up-Regulate Costimulatory Molecules during Malaria and Secrete Antibodies with T Follicular Helper Cell Support | Investigators performed longitudinal flow cytometry analyses and RNA sequencing of Plasmodium falciparum–specific B cells isolated from study participants before and shortly after febrile malaria, with simultaneous analysis of influenza hemagglutinin–specific B cells as a comparator.
[Science Immunology] |
|
|
|
Innate Immune Cell Response to Host-Parasite Interaction in a Human Intestinal Tissue Microphysiological System | The authors developed a human microphysiological system of intestinal tissue to evaluate parasite-immune–specific interactions during infection, which integrated primary intestinal epithelial cells and immune cells to investigate the role of innate immune cells during epithelial infection by the protozoan parasite, Toxoplasma gondii.
[Science Advances] |
|
|
|
Influenza Virus Replication in Cardiomyocytes Drives Heart Dysfunction and Fibrosis | To test the etiology of this aspect of the cardiac dysfunction aspect of influenza disease, researchers generated a novel recombinant heart-attenuated influenza virus via genome incorporation of target sequences for miRNAs expressed in cardiomyocytes.
[Science Advances] |
|
|
|
Profiling of hMPV F-Specific Antibodies Isolated from Human Memory B Cells | Scientists reported 113 human metapneumovirus (hMPV-F) specific monoclonal antibodies isolated from memory B cells of human donors.
[Nature Communications] |
|
|
|
In Vitro Anti-Tuberculosis Effect of Probiotic Lacticaseibacillus rhamnosus PMC203 Isolated from Vaginal Microbiota | The authors reported the anti-tubercular activities of Lacticaseibacillus rhamnosus PMC203 isolated from the vaginal microbiota of healthy women.
[Scientific Reports] |
|
|
|
Designing a Novel Multi-Epitope Vaccine against Ebola Virus Using Reverse Vaccinology Approach | Researchers employed immunoinformatics tools to design a multi-epitope vaccine against Ebola virus. They collected sequences of VP35, VP24, VP30, VP40, GP, and NP proteins from the NCBI database.
[Scientific Reports] |
| | |
|
|
|
Unexplained Post-Acute Infection Syndromes | Post-acute infection syndromes represent a substantial healthcare burden, but there is a lack of understanding of the underlying mechanisms, representing a significant blind spot in the field of medicine.
[Nature Medicine] |
|
|
|
CD4 T Cell Responses in Persistent Borrelia burgdorferi Infection | Reviewing the existing literature, scientists propose that CD4 T cells might constitute a host cell target of Borrelia burgdorferi (Bb)-mediated immune evasion, rendering these cells ineffective in orchestrating effective inflammatory responses and in supporting highly functional Bb-specific antibody induction.
[Current Opinion in Immunology] |
|
|
|
“Every Cell Is an Immune Cell; Contributions of Non-Hematopoietic Cells to Anti-Helminth Immunity” | The authors highlight the collective actions of specialized epithelial cells, stromal niches, stem, muscle and neuroendocrine cells as well as peripheral neurons in the detection and elimination of helminths at mucosal sites.
[Mucosal Immunology] |
|
|
|
|
FDA Clears COVID Booster Shot for Healthy Kids Ages 5 to 11 | US regulators on Tuesday authorized a Covid-19 booster shot for healthy 5- to 11-year-olds, hoping an extra vaccine dose will enhance their protection as infections once again creep upward.
[STAT News] |
|
|
|
The US Is About to Make a Big Gamble on Our Next COVID Winter | Experts are expected to choose a vaccine recipe for the fall, when Omicron may or may not still be the globe’s dominant variant.
[The Atlantic] |
|
|
|
Tonix Pharmaceuticals Extends Research Collaboration with the University of Alberta to Develop Antiviral Drugs Against SARS-CoV-2 | Tonix Pharmaceuticals Holding Corp. announced it has entered into a license agreement and extended a research collaboration with the University of Alberta focused on identifying and testing broad-spectrum antiviral drugs against future variants of SARS-CoV-2 and other emerging viruses.
[Tonix Pharmaceuticals Holding Corp.] |
|
|
|
|
| June 26 – 28, 2022
Basel, Switzerland |
|
|
|
|
|
| | Nationwide Children’s Hospital – Columbus, Ohio, United States |
|
|
|
| | Francis Crick Institute – London, England, United Kingdom |
|
|
|
| | STEMCELL Technologies, Inc. – Vancouver, British Columbia, Canada |
|
|
|
| | Ragon Institute of MGH, MIT and Harvard – Cambridge, Massachusetts, United States |
|
|
|
| | The Pirbright Institute – Pirbright, England, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
